News
HRTX
0.2930
+4.64%
0.0130
Heron Therapeutics Q3 Earnings Preview
Seeking Alpha · 1d ago
Largest borrow rate increases among liquid names
TipRanks · 2d ago
Xencor (XNCR) Q3 Earnings and Revenues Beat Estimates
NASDAQ · 3d ago
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 3d ago
Weekly Report: what happened at HRTX last week (1026-1030)?
Weekly Report · 6d ago
Russell 2000 estimated to drop 83 stocks in December rebalance - Stephens
Seeking Alpha · 10/29 19:44
Weekly Report: what happened at HRTX last week (1019-1023)?
Weekly Report · 10/26 09:35
CytoDyn Appoints Robert E. Hoffman As CEO; Lalezari To Focus On Research
NASDAQ · 10/20 07:28
Weekly Report: what happened at HRTX last week (1012-1016)?
Weekly Report · 10/19 09:35
Notable Wednesday Option Activity: HRTX, GLNG, KNSL
NASDAQ · 10/14 19:21
Weekly Report: what happened at HRTX last week (1005-1009)?
Weekly Report · 10/12 09:37
Weekly Report: what happened at HRTX last week (0928-1002)?
Weekly Report · 10/05 09:37
Heron Therapeutics Expands U.S. Portfolio Through Licensing Deal
TipRanks · 09/29 21:30
Heron Therapeutics enters license agreement with Long Grove, Capstone
TipRanks · 09/29 21:10
Heron Therapeutics Enters Multi-product Development And License Agreement On Sept 23, 2026; Granted Exclusive License To Market Products In U.S.; Co To Pay Milestone And Royalty Payments Under License Agreement
Benzinga · 09/29 21:07
Largest borrow rate increases among liquid names
TipRanks · 09/28 12:45
Weekly Report: what happened at HRTX last week (0921-0925)?
Weekly Report · 09/28 09:34
Weekly Report: what happened at HRTX last week (0914-0918)?
Weekly Report · 09/21 09:35
Weekly Report: what happened at HRTX last week (0907-0911)?
Weekly Report · 09/14 09:37
Weekly Report: what happened at HRTX last week (0831-0904)?
Weekly Report · 09/07 09:34
More
Webull provides a variety of real-time HRTX stock news. You can receive the latest news about Heron Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About HRTX
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutics that improve medical care. Its acute care product portfolio includes ZYNRELEF, APONVIE, CINVANTI, and SUSTOL. ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low-dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist indicated for postoperative nausea and vomiting in adults. CINVANTI is an IV formulation of aprepitant, a substance NK1 receptor antagonist. SUSTOL is the first extended-release 5-HT3 receptor antagonist approved for the prevention of acute and delayed nausea and vomiting associated with both MEC and anthracycline and cyclophosphamide combination chemotherapy regimens.